SynthesisBMC cancer2025
Curcumin in prostate cancer: a systematic review of molecular mechanisms and nanoformulated therapeutic strategies.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Nutraceuticals in Uro-Oncology: A Structured Expert Review and Precision-Oriented Framework.Nutrients · 2026Review
- Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Review
- Article
- The anti-migratory effect of curcumin in colorectal cancer involves IKKβ/NF-κB/Snail-mediated EMT inhibition.Translational cancer research · 2026Article
- Curcumin derivatives with 1,5-diaryl-3-oxo-1,4-pentadiene: novel dual-function lead compounds showing anticancer and MDR reversal effects.RSC advances · 2026Article
- Curcumin Attenuates LPS-Induced Migration/EMT and LPS/ATP-Associated IL-1β Release in Androgen-Independent Prostate Cancer Cells.Current issues in molecular biology · 2026Article
- Targeting pancreatic cancer with natural compounds: molecular mechanisms, preclinical evidence, clinical perspectives, and limitations.Frontiers in pharmacology · 2026Review
- Programmed cell death mechanisms of traditional plant medicine in prostate cancer therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is one of the most prevalent malignancies in men, often progressing to castration-resistant forms and resisting conventional therapies. Curcumin, a polyphenol from Curcuma longa, has emerged as a potent anti-cancer agent by modulating several molecular pathways.
objectiveThis systematic review seeks to synthesize current preclinical evidence on the molecular mechanisms underlying curcumin's effects in PCa and to evaluate nanoformulation strategies developed to enhance its pharmacokinetics and therapeutic efficacy.
methodsA comprehensive search of five major databases up to March 1, 2025 identified 22 eligible studies on curcumin and PCa. Data on molecular pathways, therapeutic outcomes, and delivery systems were extracted and assessed using ToxRTool and SYRCLE guidelines.
resultsCurcumin modulated key pathways including PI3K/Akt/mTOR (8 studies), NF-κB (7), AR signaling (6), and apoptosis-related regulators (13). Therapeutic outcomes included apoptosis, necroptosis, cell cycle arrest, and suppression of migration and angiogenesis. Nanoformulations (e.g., Theracurmin®, PLGA-curcumin) demonstrated improved bioavailability and tumor-targeted delivery. Synergistic combinations with docetaxel, quercetin, or phototherapy enhanced its anti-cancer effects.
conclusionCurcumin exerts multi-targeted anticancer effects in PCa models, but clinical translation is hindered by poor bioavailability. Advanced nanoformulations and rational combination therapies offer promising strategies to overcome these limitations. Clinical trials evaluating optimized curcumin delivery systems in well-defined PCa populations are strongly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.